The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences.

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...